- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 6881
View more information in the IUPHAR Pharmacology Education Project: tocilizumab
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Approved drug?||Yes (FDA (2010), EMA (2009))|
|International Nonproprietary Names|
|Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®|
|Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action  that is approved for chronic autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).
In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection in some patients and which leads to potentially life-threatening lung damage.
|GtoPdb PubChem SID||178103463|
|Search PubMed clinical trials||tocilizumab|
|Search PubMed titles||tocilizumab|
|Search PubMed titles/abstracts||tocilizumab|